Skip to content

Study · Not a test of the peptide alone · 2008

4 results

[Effects of mercazolyl and L-thyroxine on the antiedematous activity of immunotropic preparations during development of toxic brain edema and swelling].

Platonov IA, Anashchenkova TA, Andreeva TA

Eksperimental'naia i klinicheskaia farmakologiia1 Nov 2008

PMID19140517 (opens in a new tab)PepBankPUB-19140517
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01AnimalNot a test of Thymalin aloneAnimal study (in vivo)Efficacy outcome

    In rats, thyroid drugs with immune preparations including thymalin decreased brain tissue density compared with intact animals.

    In plain wordsIn rats, thyroid drugs with immune preparations including thymalin reduced brain tissue density compared with intact animals.

    Peptide
    Thymalin
    Outcome
    DecreaseBrain tissue density
    Study

    ratn: not reported in source

    Toxic brain edema and swelling with thyroid dysfunction
    Comparator
    Intact animals
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The administration of mercazolyl (5 mg/kg) and L-thyroxin (35.7 microg/kg) with thymogen (10 microg/kg), thymalin (1.2 mg/kg), cycloferon (0.5 mg/kg) results in decreasing brain tissue density as compared to intact animals.
    1 context sentence
    Summary · context
    Toxic brain edema and swelling was modeled under condition of hypo- and hyperfunction of thyroid gland.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  2. 02AnimalNot a test of Thymalin aloneAnimal study (in vivo)Efficacy outcome

    In rats, thyroid dysfunction decreased antiedematous activity of immune preparations including thymalin.

    In plain wordsIn rats, thyroid dysfunction reduced the activity against brain edema of immune preparations including thymalin.

    Peptide
    Thymalin
    Outcome
    DecreaseAntiedematous activity
    Study

    ratn: not reported in source

    Toxic brain edema and swelling with thyroid dysfunction
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Dysfunction of the thyroid gland leads to changes in pharmacodynamics of immune preparations, which results in a decrease of their antiedematous activity.
    2 context sentences
    Summary · context
    The administration of mercazolyl (5 mg/kg) and L-thyroxin (35.7 microg/kg) with thymogen (10 microg/kg), thymalin (1.2 mg/kg), cycloferon (0.5 mg/kg) results in decreasing brain tissue density as compared to intact animals.
    Summary · context
    Toxic brain edema and swelling was modeled under condition of hypo- and hyperfunction of thyroid gland.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  3. 03AnimalNot a test of Thymogen (oglufanide) aloneAnimal study (in vivo)Efficacy outcome

    In rats, thyroid drugs administered with immune preparations including thymogen decreased brain tissue density versus intact animals.

    In plain wordsIn rats, thyroid drugs with immune preparations including thymogen reduced brain tissue density compared with intact animals.

    Peptide
    Thymogen (oglufanide)
    Outcome
    DecreaseBrain tissue density
    Study

    ratn: not reported in source

    Toxic brain edema with thyroid dysfunction
    Comparator
    Intact animals
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The administration of mercazolyl (5 mg/kg) and L-thyroxin (35.7 microg/kg) with thymogen (10 microg/kg), thymalin (1.2 mg/kg), cycloferon (0.5 mg/kg) results in decreasing brain tissue density as compared to intact animals.
    1 context sentence
    Summary · context
    Toxic brain edema and swelling was modeled under condition of hypo- and hyperfunction of thyroid gland.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  4. 04AnimalNot a test of Thymogen (oglufanide) aloneAnimal study (in vivo)Efficacy outcome

    In rats, thyroid dysfunction decreased the antiedematous activity of immune preparations, including thymogen.

    In plain wordsIn rats, thyroid dysfunction reduced the activity of immune preparations, including thymogen, against brain edema.

    Peptide
    Thymogen (oglufanide)
    Outcome
    DecreaseAntiedematous activity under thyroid dysfunction
    Study

    ratn: not reported in source

    Toxic brain edema with thyroid dysfunction
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Dysfunction of the thyroid gland leads to changes in pharmacodynamics of immune preparations, which results in a decrease of their antiedematous activity.
    2 context sentences
    Summary · context
    The administration of mercazolyl (5 mg/kg) and L-thyroxin (35.7 microg/kg) with thymogen (10 microg/kg), thymalin (1.2 mg/kg), cycloferon (0.5 mg/kg) results in decreasing brain tissue density as compared to intact animals.
    Summary · context
    Toxic brain edema and swelling was modeled under condition of hypo- and hyperfunction of thyroid gland.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 12:50 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    14 Oct 2026, 05:02 UTC

    Study results updated

  3. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.